Upload Avatar (500 x 500)
Lunxiu Qin
qinlx@fudan.edu.cn
Chinese, English
Shanghai
Fudan University
Biomedical Sciences
  • 1993.9-1996.6 PhD: Shanghai Medical University, Surgery
  • 1987.9-1990.6 Master's: Xuzhou Medical College, Surgery
  • 1982.9-1987.6 Bachelor's: Xuzhou Medical College, Clinical Medicine
  • National Outstanding Youth Science Fund, National Natural Science Foundation, 2003
  • Ministry of Education Innovation Team Leader, Ministry of Education, 2011
  • Shanghai Medical Leading Talent, Shanghai Health Bureau, 2010
  • Shanghai Outstanding Academic Leader, Shanghai Science and Technology Commission, 2008
  • 2014.1-Present - Fudan University Affiliated Huashan Hospital, General Surgery, Director/Chief Physician/Professor
  • 2010.12-2013.12 - Fudan University Affiliated Zhongshan Hospital, Liver Surgery, Deputy Director/Chief Physician/Professor
  • 2005.5-Present - Fudan University Institute of Biomedical Sciences, Dual-appointed PI/Professor
  • 2001.12-2010.12 - Fudan University Affiliated Zhongshan Hospital, Liver Surgery, Chief Physician/Professor
  • 2000.5-2000.12 - Visiting Scholar, University of Hong Kong
  • 1999.1-1999.7 - Visiting Scholar, National Institutes of Health (NIH), USA
  • 1996.7-2001.11 - Fudan University Affiliated Zhongshan Hospital, Liver Surgery, Associate Professor/Associate Chief Physician
  • 1990.7-1993.8 - Xuzhou Medical College Affiliated Hospital, Surgery, Lecturer/Attending Physician
  • National Natural Science Second Prize (2010): State Council
  • Shanghai Natural Science First Prize (2009): Shanghai Association for Science and Technology
  • Ministry of Education Natural Science First Prize (2016): Ministry of Education
  • Tan Jiazhen Life Science Award (Innovation Award) (2015): Shanghai Biomedical Industry Association
  • Shanghai Science and Technology Elite (2013): Shanghai Association for Science and Technology
  • Shanghai Peony Award (2010): Shanghai Science and Technology Commission
Tumor Surgery and Basic Research
Liver Cancer Clinical Work and Metastasis Recurrence Mechanism and Prevention
  • GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis, Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, Forgues M, Jia HL, Lu L, Zhang XF, Lian BF, Xie L, Dong QZ, Tang ZY, Wang XW, Qin LX, 2016
  • MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway, Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH, Qin LX, 2014
  • MicroRNA-26a Suppresses Tumor Growth and Metastasis of Human Hepatocellular Carcinoma by Targeting IL-6-Stat3 Pathway, Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ, Qin LX, 2013
  • Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma, Dong QZ, Zhang XF, Zhao Y, Jia HL, Zhou HJ, Dai C, Sun HJ, Qin Y, Ren N, Ye QH, Qin LX, 2013
  • Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma, Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ, Ren N, Dong QZ, Zhou HJ, Ren ZG, Zhao NQ, Wang XW, Tang ZY, Qin LX, Ye QH, 2013
  • Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas, Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY, 2013
  • Association of specific genotypes in metastatic suppressor HTPAP with tumor metastasis and clinical prognosis in hepatocellular carcinoma, Ren N, Wu JC, Dong QZ, Sun HJ, Jia HL, Li GC, Sun BS, Dai C, Shi J, Wei JW, Sheng YY, Zhou HJ, Ye QH, Qin LX, 2011
  • A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients, Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW, 2010
  • Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma, Xue YH, Zhang XF, Dong QZ, Sun J, Dai C, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX, 2010
  • Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection, Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, Liu YK, Ye Q, Sun H, Zhu X, Fu L, Guo K, Gao D, Sun J, Yan Z, Ren N, Tang Z, Qin L, 2010
  • Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma, Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, Ren N, Qin LX, 2008
Tumor Surgery Basic Research Liver Cancer Clinical Work Metastasis Recurrence Mechanism Prevention Treatment

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.